Sightful Invest
  • Business
  • Investing
  • Politics
  • Stock
Top Posts
‘It’s sort of scary’: Officials flag surprising revelations...
Loyal Jill Biden aide’s deposition date comes with...
Iran’s leader threatens ‘even bigger blow’ against US,...
Bondi should release ‘credible’ Epstein files, Trump says
Jill Biden ‘work husband’ pleads Fifth Amendment, dodges...
Senate to debate Trump’s $9B clawback bill after...
Trump’s controversial plan to fire federal workers finds...
Loyal Jill Biden aide arrives for sworn deposition...
Conservative legal group presses agency to act on...
EXCLUSIVE: Trump admin strengthens religious accommodations in federal...
  • Business
  • Investing
  • Politics
  • Stock

Sightful Invest

Investing

RAD Increases Ownership in Radiopharm Ventures to 75%

by admin August 26, 2024
August 26, 2024
RAD Increases Ownership in Radiopharm Ventures to 75%

Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical needs, is pleased to announce that it has increased its ownership stake in Radiopharm Ventures, LLC, a joint venture created with The University of Texas MD Anderson Cancer Center, from 51% to 75%.

Radiopharm Ventures, LLC, is a joint venture created in Q3 2022 between MD Anderson and Radiopharm Theranostics
Leading candidate B7H3 mAb is successfully completing preclinical studiesB7H3 Phase I therapeutic clinical trial planned to start in H1 CY2025B7H3 Phase 1 will be the first clinical trial globally targeting B7H3 as with a systemic radiopharmaceuticalTwo additional preclinical Radiopharm Ventures’ assets show early positive results – move to final candidate selection

The move to an increased ownership percentage comes as the joint venture continues to show promising progress in its cancer therapeutic pipeline, including the advancement of its leading B7H3 candidate and other preclinical assets.

B7-H3 is an immune checkpoint protein that is very infrequently seen in the majority of healthy cells but it is consistently abnormally overexpressed in the majority of cancer tissues. High expression of B7H3 in cancer is associated with greater tumor size and lymphatic invasion.

The B7H3 monoclonal antibody (mAb) lead candidate is successfully completing preclinical studies.

The company plans to initiate a Phase I therapeutic trial in the first half of calendar 2025, making a significant step toward clinical application.

Additionally, two other preclinical candidates have demonstrated early positive results and have progressed towards final candidate selection, with potential applications across multiple solid tumour types.

To support these advancements and its ownership percentage increase to 75%, Radiopharm has committed an additional USD$4.0 million to the joint venture, to cover future preclinical and clinical expenses.

Radiopharm and MD Anderson launched Radiopharm Ventures, LLC in September 2022 to develop novel radiopharmaceutical products for cancer treatment. The joint venture leverages MD Anderson’s expertise in antigen discovery and molecular imaging alongside Radiopharm’s capabilities in developing radiopharmaceutical therapies.

Riccardo Canevari, CEO & Managing Director of Radiopharm, commented: ‘We are encouraged by the progress to date within Radiopharm Ventures. The increased ownership by RAD, coupled with the advancements in the associated programs, positions us well to enter a Phase 1 clinical trial with B7H3 next year.”

Click here for the full ASX Release

This post appeared first on investingnews.com

previous post
Falco Announces Creation of Technical and Strategic Committees With Glencore Canada Corporation
next post
Disney tries to silence grieving husband and learns not all news is good news

You may also like

Should You Invest in Silver Bullion? (Updated 2024)

November 1, 2024

Randy Smallwood: Gold Price Strong, Now it’s Time...

March 25, 2025

Boab Metals: Advancing Toward Near-Term Lead, Silver Production...

January 15, 2025

FPX Nickel

August 2, 2024

CleanTech Lithium

August 14, 2024

Element79 Gold Corp. Provides Update on Chachas General...

April 18, 2025

Andrew O’Donnell: Gold, Silver, Energy Transition — Where...

January 21, 2025

Brunswick Exploration Announces AGM Results

June 14, 2025

Rick Rule: Gold Stock Sweet Spot, Uranium’s New...

January 24, 2025

5 Biggest Blockchain ETFs in 2025

June 4, 2025

Recent Posts

  • ‘It’s sort of scary’: Officials flag surprising revelations from deep State Department cuts
  • Loyal Jill Biden aide’s deposition date comes with no sign if he’ll appear
  • Iran’s leader threatens ‘even bigger blow’ against US, Trump says he’s in ‘no rush’ to talk
  • Bondi should release ‘credible’ Epstein files, Trump says
  • Jill Biden ‘work husband’ pleads Fifth Amendment, dodges House GOP cover-up probe questions

    Become a VIP member by signing up for our newsletter. Enjoy exclusive content, early access to sales, and special offers just for you! As a VIP, you'll receive personalized updates, loyalty rewards, and invitations to private events. Elevate your experience and join our exclusive community today!


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Categories

    • Business (826)
    • Investing (2,541)
    • Politics (3,146)
    • Stock (4)
    • About us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: sightfulinvest.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2024 Sightful Invest. All Rights Reserved.